Todd M Morgan
Overview
Explore the profile of Todd M Morgan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
280
Citations
5437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tosoian J, Zhang Y, Meyers J, Heaton S, Siddiqui J, Xiao L, et al.
J Urol
. 2025 Jan;
:101097JU0000000000004421.
PMID: 39836866
Purpose: The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of grade group ≥ 2 (GG ≥ 2) prostate cancer using post-digital rectal examination (DRE) urine. To improve...
2.
Lapedis C, Kurnot S, Bergholtz S, Owens S, Hawley S, Morgan T, et al.
JAMA
. 2025 Jan;
333(8):717-718.
PMID: 39745765
No abstract available.
3.
Patel P, Nallandhighal S, Scoville D, Cotta B, Knuth Z, Triner D, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39613543
Background And Objective: Prostate cancer (PC) in the transition zone (TZ) has better prognosis than peripheral-zone (PZ) PC despite higher prostate-specific antigen (PSA) in patients with TZ tumors. Our aim...
4.
Tward J, Huang H, Esteva A, Mohamad O, van der Wal D, Simko J, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400145.
PMID: 39447096
Purpose: Current clinical risk stratification methods for localized prostate cancer are suboptimal, leading to over- and undertreatment. Recently, machine learning approaches using digital histopathology have shown superior prognostic ability in...
5.
Lazarovich A, Kristof T, Steadman S, Dahmen A, Josephson M, Barth R, et al.
BJU Int
. 2024 Oct;
135(2):339-345.
PMID: 39385314
Objective: To analyse the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation, as the impact of organ transplantation and associated immunosuppression on the...
6.
Abusamra S, Solorzano M, Quarles J, Luke M, Patel M, Vince Jr R, et al.
Urol Pract
. 2024 Oct;
12(1):63-72.
PMID: 39383006
Introduction: There is increasing awareness that patients with prostate cancer frequently harbor germline variants that may carry important implications for them and their family members. Given the variable clinical guidelines,...
7.
Morgan T, Daignault-Newton S, Spratt D, Dunn R, Dunn R, Singhal U, et al.
Eur Urol
. 2024 Oct;
87(2):228-237.
PMID: 39379238
Background And Objective: Decipher is a tissue-based genomic classifier (GC) developed and validated in the post-radical prostatectomy (RP) setting as a predictor of metastasis. We conducted a prospective randomized controlled...
8.
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, et al.
BMC Public Health
. 2024 Sep;
24(1):2533.
PMID: 39289635
Background: Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is...
9.
Lenz L, Clegg W, Iliev D, Kasten C, Korman H, Morgan T, et al.
Prostate Cancer Prostatic Dis
. 2024 Sep;
PMID: 39237680
Background: Genomic testing can add risk stratification information to clinicopathological features in prostate cancer, aiding in shared medical decision-making between the clinician and patient regarding whether active surveillance (AS) or...
10.
Pockros B, Davenport M, Mead M, Talwar R, Kaffenberger S, Sekar R, et al.
Urol Pract
. 2024 Aug;
11(6):915-917.
PMID: 39196665
No abstract available.